Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia

Leuk Res. 2022 May:116:106823. doi: 10.1016/j.leukres.2022.106823. Epub 2022 Mar 9.

Authors

Úna Bhreathnach¹, Dearbhla Doherty², Karen Murphy², Catherine M Flynn³, Stephen E Langabeer⁴

Affiliations

¹ Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 W9RT, Ireland.
² Department of Haematology, St. Vincent's University Hospital, Dublin D04 T6F4, Ireland.
³ Department of Haematology, St. James's Hospital, Dublin D08 RX0X, Ireland.
⁴ Cancer Molecular Diagnostics, St. James's Hospital, Dublin D08 W9RT, Ireland. Electronic address: [email protected].

PMID: 35303627
DOI: 10.1016/j.leukres.2022.106823

No abstract available

Keywords: 16); Allogeneic stem cell transplantation; KAT6A-CREBBP; Minimal Residual Disease; Secondary AML; t(8.

Publication types

Letter

MeSH terms

CREB-Binding Protein
Histone Acetyltransferases
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Neoplasm, Residual

Substances

CREB-Binding Protein
CREBBP protein, human
Histone Acetyltransferases
KAT6A protein, human